中國支付通(08325.HK)出售附屬公司股份 套現2.2億元
中國支付通(08325.HK)公布,公司已有條件同意向Geerong (HK) Limited及橡樹灣國際有限公司,出售合共75股建佳投資有限公司普通股,相當於其目前全部已發行股本75%,代價總額為2.25億元。
完成後,建佳投資有限公司將不再為公司的附屬公司,而將成為集團的聯營公司。
公司指,出售事項所得款項淨額將約為2.24億元。集團計劃將所得款項淨額約1.9億元用作償還其部分現有債項,並將其中約3,360萬元用作集團的一般營運資金。出售事項為集團提供變現於目標集團的部分投資及改善其償債能力狀況的良機。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.